Germany· DE-A57-5a0cdfe3eab12f34
Feiba
A medicinal product containing factor viii inhibitor bypassing fraction, registered in Germany by Takeda Gmbh.
Checked against EMA Article 57 (European Union) on
Informational only — not a medical device.
The record
At a glance
EMA Article 57 (European Union)- Active substance
- Factor Viii Inhibitor Bypassing Fraction
- Manufacturer
- Takeda Gmbh
- Country
- Germany (DE)
- ATC code
- —
- Reimbursed
- Not published by this register
- Source register
- EMA Article 57 (European Union)
- Last checked
- September 30, 2026
Packs & prices · 0
No packs listed by the register for this record.
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Factor viii inhibitor bypassing fraction in 7 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- United KingdomFEIBA 100units/ml (1,000unit) powder and 10ml solvent for solution for infusion vialsTakeda UK Ltd
- FinlandFeibaBaxalta Innovations GmbH
- CanadaFEIBA NFTAKEDA CANADA INC
- BelgiumFeiba 1000 UBaxalta Innovations
- IrelandFEIBA 100 U/ml powder and solvent for solution for infusionBaxalta Innovations GmbH
- NorwayFeibaBaxalta Innovations GmbH
- SwedenFeiba 100 E/ml Pulver och vätska till infusionsvätska, lösningBaxalta Innovations GmbH
Authorised across Europe · EMA
The same active substance is authorised in 27 EEA countries. Names it is sold under:
- Austria · Feiba
- Belgium · Feiba
- Bulgaria · Фейба
- Cyprus · Feiba
- Czechia · Feiba
- Denmark · Feiba
- Estonia · Feiba
- Spain · Feiba
- Finland · Feiba
- France · Feiba
- United Kingdom (Northern Ireland) · Feiba
- Greece · Feiba
- Croatia · Feiba
- Hungary · Feiba Nf
- Ireland · Feiba
- Italy · Feiba
- Lithuania · Feiba
- Latvia · Feiba
- Malta · Feiba
- Netherlands · Feiba
- Norway · Feiba
- Poland · Feiba Nf
- Portugal · Feiba Nf
- Romania · Feiba
- Sweden · Feiba
- Slovenia · Feiba
- Slovakia · Feiba
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of EMA Article 57 (European Union). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/f63657a0-d812-4d71-98db-911d156357e3 GET /v1/drugs/f63657a0-d812-4d71-98db-911d156357e3?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"pzn": null,
"route": "Intravenous Use",
"source": "ema_art57_de",
"ma_number": null,
"substance": "Factor Viii Inhibitor Bypassing Fraction",
"atc_from_source": null,
"authorisation_country": "Germany"
}See everything about factor viii inhibitor bypassing fraction.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.